Konstantin Adamsky
Director/Board Member chez FILAMENT HEALTH CORP.
Profil
Konstantin Adamsky is currently the Chief Executive Officer at Negev Labs and an Independent Director at Filament Health Corp.
He previously worked as the Co-Chief Executive Officer & Director at Targia Pharmaceuticals Ltd.
in 2016, Vice President-Operations at Regenera Pharma Ltd.
from 2017 to 2020, and as VP Operations & Technology at Levco Pharmaceuticals Ltd.
He holds a doctorate degree from the Weizmann Institute of Science.
Postes actifs de Konstantin Adamsky
| Sociétés | Poste | Début |
|---|---|---|
| FILAMENT HEALTH CORP. | Director/Board Member | 23/08/2022 |
Anciens postes connus de Konstantin Adamsky
| Sociétés | Poste | Fin |
|---|---|---|
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Chief Executive Officer | 01/08/2017 |
| Levco Pharmaceuticals Ltd. | Chief Operating Officer | - |
Formation de Konstantin Adamsky
| Weizmann Institute of Science | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FILAMENT HEALTH CORP. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
| Levco Pharmaceuticals Ltd. |
